Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat A

First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicityHuman ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies in 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a pre-clinical stage biotechnology com...

Related Keywords

Ankyra ,Ankara ,Turkey ,Cambridge ,Cambridgeshire ,United Kingdom ,Howardl Kaufman ,Joan Bosisio ,Veterinary Cancer Society ,Verge Scientific Communications ,University Of Illinois ,University Of Illinois College Veterinary Medicine ,Cancer Center ,Ankyra Therapeutics ,Illinois College ,Timothy Fan ,Associate Director ,Investor Inquiries ,Media Inquiries ,